Over 7.5 million people will suffer from dementia from Alzheimer’s disease (AD) in the next decade, bringing a host of physical, emotional and legal challenges to those impacted by this degenerative illness and to their caregivers. Professor Betsy J. Grey makes a comprehensive and timely examination of questions that should be considered when it comes to the application of testing for biomarkers for AD in determining what she considers one of society’s most weighty decisions&mdash
ARTICLE ACCESS REQUIRED
Please Log in if you are currently a Trust&Estates subscriber, or select DAYPASS for our new 24 hour access (nominal fee required).
If you are interested in unlimited article access for one year, please select Annual Subscription below.